Bioenvision to Hold Fiscal 2007 First Quarter Financial Results Conference Call Thursday, November 9, 2006
November 02 2006 - 4:46PM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) will release fiscal 2007 first
quarter financial results at 7:00 a.m. Eastern Standard Time on
November 9, 2006. Christopher B. Wood, Chairman and CEO and David
P. Luci, CFO and General Counsel, will host an investment
conference call beginning at 12:00 p.m. Eastern Standard Time on
November 9, 2006 to discuss these results and to answer questions.
Conference Call Information: Date: 11/9/06 Time: 12:00PM Eastern
Toll free (US & Canada): 866-585-6398 International:
416-849-9626 Web cast: www.bioenvision.com A replay of the call and
web cast will be available for 14 days. Replay number (US &
Canada): 866-245-6755 Replay number international: 416-915-1035
Replay passcode: 816197 Web cast replay: www.bioenvision.com About
Bioenvision Bioenvision's primary focus is the acquisition,
development, distribution and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra�, Modrenal� (for which Bioenvision has obtained regulatory
approval for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products. Bioenvision is also developing
anti-infective technologies, including the OLIGON� technology, an
advanced biomaterial that has been incorporated into various FDA
approved medical devices and Suvus�, an antimicrobial agent
currently in clinical development for refractory chronic hepatitis
C infection. For more information on Bioenvision please visit our
Web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements. Bioenvision,
Inc. (NasdaqGM:BIVN) will release fiscal 2007 first quarter
financial results at 7:00 a.m. Eastern Standard Time on November 9,
2006. Christopher B. Wood, Chairman and CEO and David P. Luci, CFO
and General Counsel, will host an investment conference call
beginning at 12:00 p.m. Eastern Standard Time on November 9, 2006
to discuss these results and to answer questions. -0- *T Conference
Call Information: Date: 11/9/06 Time: 12:00PM Eastern Toll free (US
& Canada): 866-585-6398 International: 416-849-9626 Web cast:
www.bioenvision.com A replay of the call and web cast will be
available for 14 days. Replay number (US & Canada):
866-245-6755 Replay number international: 416-915-1035 Replay
passcode: 816197 Web cast replay: www.bioenvision.com *T About
Bioenvision Bioenvision's primary focus is the acquisition,
development, distribution and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
Evoltra(R), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON(R)
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus(R), an antimicrobial
agent currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our Web site at www.bioenvision.com. Certain statements
contained herein are "forward-looking" statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
More Bioenvision, Inc. News Articles